<!doctype html>
<html lang="en">
    <head>
        <meta charset="utf-8"/>
        <meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no"/>
        <meta name="format-detection" content="telephone=no"/>
        <meta name="apple-mobile-web-app-capable" content="yes"/>
        <meta name="apple-mobile-web-app-status-bar-style" content="black"/>
        <title><!-- Key Message Description --></title>
        <link rel="stylesheet" href="../shared/shared-dificid-v4/js/ext/avModal/themes/default.css"/>
        <link rel="stylesheet" href="../shared/shared-dificid-v4/css/shared-main.css"/>
        <link rel="stylesheet" href="css/specific.css"/>
    </head>
    <body data-pix="true" data-SlideName="Conclusions">
    	<section id="wrapper">
            <!-- Landscape Header with Tracking -->
    		<header class="landscapeHeader">
            <div class="homeIcon" data-slide="0.0_dificid_v4_home.zip">&nbsp;</div>
                <div class="halfMoon" id="halfMoonTOC">&nbsp;</div>      
            </header>
           
    		<section id="contentWrapper">
    			<div id="content"> <!--====== main content Starts ========--> 
                    <!-- Navigation Starts-->
                    <nav data-count="six">&nbsp;</nav>
                    <!-- Navigation Ends --> 
                    <!-- Landscape Start -->
                    <div id="landscape">
                        <!-- Slide Specific Code Start -->
                        <section>
                            <!-- <div class="title darkGreen light fs29">Conclusions and limitations
                            </div>
                           <ul class="conclusions">
                               <li class="limitations">dgjhlkj</li>
                           </ul>
                            <hr class="lightGreen homeHR"> -->
                            
                                
                            
                            <div class="bgWhiteBox">
                                <div class="upperborder">
                                <div class="overlay">
                                    <h1 class="title  darkGreen light fs29 conclusion">
                                        Conclusions and limitations
                                    </h1>
                                </div>    
                                    <div class="assumScrollbarContent content bottomScroll">
                                        <h3 class="optimal darkGreen helveticaBold fs18">
                                            Optimal treatment regimens for CDI were:

                                        </h3>
                                        <p class="fidaxomicin light fs16 darkGreen">
                                            Fidaxomicin for non-severe initial CDI
                                        </p>
                                        <div class="border">
                                            &nbsp;
                                        </div>
                                        <p class="Vancomycin light fs16 darkGreen">
                                            Vancomycin for severe CDI
                                        </p>
                                        <div class="borderOne">
                                            &nbsp;
                                        </div>
                                         <p class="recurrence light fs16 darkGreen">
                                            Fidaxomicin for first recurrence
                                        </p>
                                        <div class="borderTwo">
                                            &nbsp;
                                        </div>
                                        <p class="fecal light fs16 darkGreen">
                                            Fecal microbiota transplant (FMT) for subsequent recurrence
                                        </p>
                                    
                                            <ul class="limitations fs14 lh18">
                                                <li>
                                                   Results were consistent with prior literature that supports earlier use of fidaxomicin<br/> (either for initial treatment of CDI or first recurrence)     
                                                </li>
                                                <li class="effective">
                                                    <span class="bulletnew">The most effective treatments, with highest cure rates, are also cost-effective due to <br/>
                                                     <span class="averted"><span class="innerAdverted">—</span> Averted mortality <br/><span class="innerAdverted">—</span> Utility loss <br/><span class="innerAdverted">—</span> Costs of re-hospitalization and/or further treatments for recurrent CDI </span> </span>     
                                                </li> 
                                                
                                                <li class="Metronidazolenew">
                                                    Metronidazole is suboptimal for non-severe CDI as it is less beneficial than<br/> alternative strategies
                                                </li>
                                                <li class="MetronidazoleOne">
                                                    Fidaxomicin and FMT should take a more prominent role in the management of<br/> recurrent CDI due to the cost-effective nature of these therapies  

                                                </li>
                                            </ul>
                                            <div class="topspace">
                                            <h3 class="limit darkGreen helveticaBold fs18">
                                            Limitations

                                        </h3>
                                        
                                            <ul class="second fs14 lh18">
                                                <li>
                                                  Study did not stratify individuals into risk categories for recurrence, such as those with<br/> inflammatory bowel disease, transplant patients, or malignancy. These subgroups may have higher risk of recurrence and additional factors related to their underlying disease that would certainly affect treatment outcomes and costs     
                                                </li>
                                                <li>
                                                     Study did not incorporate prior antibiotic exposure into model        
                                                </li> 
                                                
                                                <li>
                                                   Study did not model prophylactic vancomycin with systemic antibiotics
                                                </li>
                                                <li>
                                                   FMT was limited to second or subsequent recurrence per IDSA/SHEA guidelines 

                                                </li>
                                                <li>
                                                  Input parameters for CDI proportion hospitalized, and hospital length of stay were taken from a single study, and in reality are likely highly variable 

                                                </li>
                                                <li>
                                                   No direct comparisons of all therapies for second and subsequent recurrence <br/> were available  

                                                </li>
                                                <li>
                                                Many of the input parameters come from small studies, including some populations with inflammatory bowel disease, which may not represent the general population. Study attempted to account for this variability using the probabilistic sensitivity analysis<br/> and still found the results to be robust
                                                </li> 
                                            </ul>
                                            </div>

                                </div>
                                     <div class="footerNote fs14 helveticaRoman">
                                    Provided pursuant to FDAMA  &sect; <span class="footerNumber">114.</span> 
                            </div>  
                            </div>

                            </div>
                        </section>
                        <!-- Slide Specific Code End -->
                        
                        <!-- SmartBalance Headline Start -->
                        <div class="ssiTxt">
                            Important Safety Information
                        </div>
                        <!-- SmartBalance Headline End -->
                        
                        <!-- SmartBalance Content starts -->
                        <section id="smartBalance">&nbsp;</section>
                        <!-- SmartBalance Content ends -->
                    </div>
                    <!-- Landscape End -->
                   
    			</div> <!--======== main content Ends ===========-->
    		</section><!--//contentWrapper-->

    		<footer data-count="six">&nbsp;</footer>
    	</section><!--//wrapper-->

    	<!-- ================= Global popups Start=====================-->
        <section id="globalComponent">&nbsp;</section>
    	<!-- ================= Global popups End=====================-->
       
        <script src="../shared/shared-dificid-v4/js/jquery-2.2.3.min.js" charset="utf-8"></script>
        <script src="../shared/shared-dificid-v4/shared-main.js" charset="utf-8"></script>
    </body>
</html>